Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mayne Pharma GroupMAYNF 56 Earnings per Share (Diluted) is $-0.69 as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 56/100 and a GF Value™ of $3.54 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 101 Medical Distribution companies, Mayne Pharma Group ranks better than 61.39% on this metric.
Mayne Pharma Group's EPS (Basic) for the
six
months ended in Dec. 2025 was $-0.12.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.69.
During the past 3 years, the average EPS without NRIGrowth Rate was 9.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -54.20% per year.
During the past 13 years, Mayne Pharma Group's highest 3-Year average EPS without NRI Growth Rate was 30.80% per year. The lowest was -139.00% per year. And the median was -12.20% per year.
Mayne Pharma Group (OTCPK:MAYNF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Mayne Pharma Group Earnings per Share (Diluted) Related Terms
Mayne Pharma Group Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group Earnings per Share (Diluted) Chart
MAYNF vs MCK, COR, CAH: Earnings per Share (Diluted) Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's PE Ratio distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's PE Ratio falls into.
Mayne Pharma Group Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Mayne Pharma Group's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.69 mean?
Mayne Pharma Group (MAYNF) has a Earnings per Share (Diluted) of $-0.69 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #39 out of 101 companies in the Medical Distribution industry, placing it in the top 38.6%.
Is Mayne Pharma Group's Earnings per Share (Diluted) too high?
Mayne Pharma Group's current Earnings per Share (Diluted) is $-0.69. Based on the distribution chart, Mayne Pharma Group ranks #39 out of 101 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Earnings per Share (Diluted) compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #39 out of 101 companies for Earnings per Share (Diluted). This puts Mayne Pharma Group in the upper half of its industry. The industry median Earnings per Share (Diluted) is 2.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Distribution company?
The median Earnings per Share (Diluted) among Medical Distribution companies is 2.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Earnings per Share (Diluted) is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Earnings per Share (Diluted) is $-0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.54, compared to a current price of $2.31 — trading 34.7% below its estimated fair value. The current Earnings per Share (Diluted) is $-0.69. Mayne Pharma Group's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Earnings per Share (Diluted) is $-0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $2.31 is trading 34.7% below its estimated GF Value™ of $3.54.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Earnings per Share (Diluted): $-0.69
GF Value™: $3.54 vs. price of $2.31 (34.7% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
56GF Score
Get the complete analysis for MAYNF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
